SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022

[July 04, 2014]

Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/jttbnt/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Japan Drug Forecast and Market Analysis to 2022" report to their offering.

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most sgnificant has been the inclusion of males in routine vaccine recommendations in some countries.


Scope

  • Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Prophylactic Human Papillomavirus Vaccines disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the Japan

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Vaccination Recommendations and Coverage Rates

5 Competitive Assessment

6 Unmet Need and Opportunity

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/jttbnt/pharmapoint


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy